(19) World Intellectual Property Organization International Bureau



(43) International Publication Date 21 September 2006 (21.09.2006)

(10) International Publication Number WO 2006/097848 A1

(51) International Patent Classification:

C07D 405/06 (2006.01)

C07D 401/04 (2006.01)

C07D 405/14 (2006.01)

A61K 31/454 (2006.01)

C07D 211/34 (2006.01)

A61P 31/18 (2006.01)

C07D 471/04 (2006.01)

(21) International Application Number:

PCT/IB2006/000876

(22) International Filing Date:

6 March 2006 (06.03.2006)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 60/663,049

17 March 2005 (17.03.2005)

(71) Applicant (for all designated States except US): PFIZER INC. [US/US]; 235 East 42nd Street, New York, NY 10017 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): BLAIR, Wade, Stanton [US/US]; Agouron Pharmaceuticals Inc., A Pfizer Company, 10777 Science Center Drive, San Diego, CA 92121 (US). BUTLER, Scott, Lee [US/US]; Agouron Pharmaceuticals Inc., A Pfizer Company, 10777 Science Center Drive, San Diego, CA 92121 (US). CAO, Joan, Oun [CA/US]; Agouron Pharmaceuticals Inc., A Pfizer Company, 10777 Science Center Drive, San Diego, CA 92121 (US). CHU, Wai-Lam, Alexis [US/US]; Cove View Place, San Diego, CA 92154 (US). JACKSON, Roberta, Lynn [US/US]; Agouron Pharmaceuticals Inc., A Pfizer Company, 10777 Science Center Drive, San Diego, CA 92121 (US). PATICK, Amy, Karen [US/US]; Agouron Pharmaceuticals Inc., A Pfizer Company, 10777 Science Center Drive, San Diego, CA 92121 (US). PENG. Qinghai [US/US]; Agouron Pharmaceuticals Inc., A Pfizer Company, 10777 Science Center Drive, San Diego, CA 92121 (US).

- (74) Agents: FULLER, Grover, F, Jr. et al.; c/o LAWRENCE, Jackie, Pfizer Inc. MS8260-1615, Eastern Point Road, Groton, CT 06340 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM). European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: HTV-1 VIRION MATURATION INHIBITORS, COMPOSITIONS AND TREATMENTS USING THE SAME

(57) Abstract: The present invention provides compounds of Formula I, II, III or IV, or pharmaceutically acceptable salts and solvates thereof, which are useful as inhibitors of human immunodeficiency virus (HIV) and are also useful for the treatment of HIV infections in HIV- infected mammals, including humans. The present invention also provides pharmaceutical compositions comprising compounds of Formula I1 II, III or IV, and their pharmaceutically acceptable salts and solvates.

WO 2006/097848